CRISPR and Genome Editing – Products

CAR-T Target Luciferase Reporter Cells that have high endogenous expression of CD19, CD20, and HER2, which makes them more physiologically relevant as in vitro tools to develop adoptive CAR-T cell therapies.

These materials highlight the use of single cell dispensers that enhance efficiency and predictability, improving workflow robustness to support safe and cost-effective biopharmaceutical manufacturing.

Laverock Therapeutics secures £1m funding via the Innovate UK Investor Partnerships Future Economy programme, supported by UKI2S.

These whitepapers highlight how optimized CRISPR protocols and site-specific knock-in technology can be used to engineer simple or complex genetic modifications in allogenic iPSCs.

Research published in Molecular Cell used INDUCE-seq to identify DNA topology as an important regulator of CRISPR targeting specificity. Peer-reviewed data demonstrates the sensitivity of INDUCE-seq DNA break mapping platform.

Expanded footprint, new capabilities mark IDT’s entrance into CRISPR therapeutics space.

Takara Bio Inc. announces that it has entered into a License Agreement with non-profit/charity organization, Fondazione Telethon ETS Italy, under which Takara Bio grants Telethon a commercial license to use RetroNectin®.

Investment to expand cell line development capabilities and accelerate customer workflows, as part of its diverse and tailored antibody solutions.

Thermo Fisher Scientific TSX and TDE Series ultra-low freezers are tested according to ISO 14644-14 and designated ISO Class 5.5; operational; 0.1 μm, 0.2 μm, 0.3 μm, 0.5 μm, 1.0 μm, contributing to the safe and effective development of therapies.

Under the new agreement, Integrated DNA Technologies (IDT) will sell Aldevron cGMP-manufactured CRISPR nucleases to enable customers to rapidly transition from discovery to clinic.